Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT323 versus investigator's choice chemotherapy in previously treated HER2-expressing recurrent endometrial cancer
2023-507525-42-00Phase 3Authorised
- Sponsor
- BioNTech SE
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of trastuzumab pamirtecan in endometrial cancer (EC) (2 arms), sponsored by BioNTech SE. Primary endpoints: Progression-free survival by blinded independent central review and Objective response rate by blinded independent central review. Planned start Dec 2025; status: authorised.
02
Drugs
trastuzumab pamirtecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2023-507525-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507525-42-00.